Investors

Overview

Webcast ImageWebcast
CTI BioPharma Corp at the Oppenheimer’s 29th Annual Healthcare Conference (Replay)
03/19/19 at 4:30 p.m. ET

CTI BioPharma is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. CTI BioPharma has a late-stage development pipeline, including pacritinib, CTI BioPharma’s lead product candidate for the treatment of patients with myelofibrosis. CTI BioPharma is headquartered in Seattle, Washington. Our management and investor relations team provide updates throughout the year through conference calls, investor events, press releases and SEC filings. We invite you to sign up for our investor alerts and listen to our archived and live presentations.

To CTI’s knowledge, all press releases, scientific papers and abstracts, and the information contained within them were timely and accurate when issued. The continued accuracy of this material beyond the date of issuance and posting on the website is not assured. CTI has no intention of updating this information and specifically disclaims any duty to do so. These documents may contain forward-looking statements. Actual results could vary dramatically as a result of known and unknown risks and uncertainties. Please see Terms of Use for this website.

IR Contact

 
  • Current Quote
  • Stock Chart
NASDAQ:CTIC
$0.95 - 0.02 (1.04%)
Day High:$1.01
Day Low:$0.95
Volume:70,486
03/25/1910:03 a.m. ET
Delayed at least 15 minutes.

Maeve Conneighton
Ph +1-212-600-1902
CTI@argotpartners.com


 

Recent News

MORE
DateTitle 
Mar 13, 2019CTI BioPharma Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Highlights
SEATTLE, March 13, 2019 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today reported financial results for the fourth quarter and full year ended December 31, 2018. "The Company is focused on advancing its development program of pacritinib for the treatment for myelofibrosis patients with severe thrombocytopenia in the United States and Europe in 2019," commented Adam R. Craig, M.D., Ph.D., President and Chief Executive Officer of CTI BioPharma. "Following the previously-announced completi... 
Printer Friendly Version
Mar 12, 2019CTI BioPharma to Present at Oppenheimer's 29th Annual Healthcare Conference on Tuesday, Mar. 19
SEATTLE, March 12, 2019 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at Oppenheimer's 29th Annual Healthcare Conference at 4:30 p.m. EDT at the Westin New York Grand Central. Presentation details: Event:           Oppenheimer's 29th Annual Healthcare Conference Date:              Tuesday... 
Printer Friendly Version
Feb 20, 2019CTI BioPharma to Present at the 8th Annual SVB Leerink Global Healthcare Conference Wednesday, Feb. 27
SEATTLE, Feb. 20, 2019 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the 8th Annual SVB Leerink Global Healthcare Conference at 11:30 a.m. EST at the Lotte New York Palace Hotel. Presentation details: Event: 8th Annual SVB Leerink Global Healthcare Conference ... 
Printer Friendly Version

Events

MORE
There are currently no events scheduled.

Presentation

DateTitle
March 2019
Download Documentation CTI BioPharma Corporate Presentation
Get help downloading or viewing the above file types
Data provided by Nasdaq. Minimum 15 minutes delayed.